Healthcare


 InteliCare Expands Aged Care Tech With Major Sector Deal

InteliCare Expands Aged Care Tech With Major Sector Deal

March 12, 2026 09:48 PM AEDT| By Sam

InteliCare Holdings (ASX:ICR) expands its aged care technology footprint through a multi-year agreement deploying predictive analytics and IoT solutions across Victorian facilities, supporting digital transformation in residential care.

 Clarity Pharma Trial Momentum Draws Market Attention

Clarity Pharma Trial Momentum Draws Market Attention

March 12, 2026 08:37 PM AEDT| By Sam

Clarity Pharmaceuticals advances its AMPLIFY clinical trial recruitment, drawing attention to radiopharmaceutical innovation and prostate cancer imaging research while reinforcing industry focus on advanced diagnostic technologies.

 Racura Oncology Expands Share Base With New ASX Quotation

Racura Oncology Expands Share Base With New ASX Quotation

March 12, 2026 04:40 PM AEDT| By Sam

A biotechnology company applies to quote additional ordinary shares on the Australian exchange, reflecting routine capital structure management while continuing research programs focused on innovative cancer treatment development.

 HeraMED Share Expansion Draws Attention Across ASX Market

HeraMED Share Expansion Draws Attention Across ASX Market

March 12, 2026 11:49 AM AEDT| By Sam

HeraMED expands its listed share base through the quotation of new equity, illustrating how capital structure adjustments influence liquidity and transparency across Australia’s healthcare technology segment.

 Cyclopharm Share Update: What the New ASX Listing Move Signals

Cyclopharm Share Update: What the New ASX Listing Move Signals

March 12, 2026 11:41 AM AEDT| By Sam

Cyclopharm progresses a routine share quotation step on the Australian exchange, highlighting how healthcare technology companies manage equity structures while maintaining engagement with the broader Australian capital market.

 ASX 200 Faces Pressure as Strait of Hormuz Tensions Rise

ASX 200 Faces Pressure as Strait of Hormuz Tensions Rise

March 12, 2026 11:08 AM AEDT| By Sam

Rising geopolitical tensions and evolving lithium demand are shaping Australian market sentiment. Liontown Resources highlights the growing importance of battery minerals as global energy systems transition toward electrification.

 ASX Compliance Action Puts Spotlight on OncoSil Securities

ASX Compliance Action Puts Spotlight on OncoSil Securities

March 11, 2026 05:25 PM AEDT| By Sam

Exchange oversight temporarily paused quotation of a specialised healthcare security class, highlighting the importance of listing rule compliance, transparency, and structured governance within Australia’s regulated public market environment.

 Imugene Capital Raise Drives Azer-Cel Cancer Program Forward

Imugene Capital Raise Drives Azer-Cel Cancer Program Forward

March 11, 2026 05:22 PM AEDT| By Sam

Imugene Ltd launches a major capital raise to support azer-cel cancer therapy development, expand clinical trials, and strengthen its immuno-oncology pipeline while advancing research within Australia’s biotechnology sector.

 Clarity Pharma’s New Share Move Grabs ASX Attention

Clarity Pharma’s New Share Move Grabs ASX Attention

March 11, 2026 04:20 PM AEDT| By Sam

A biotechnology company’s new share quotation request highlights ongoing capital activity within Australia’s healthcare innovation sector while reflecting the strategic role equity instruments play in supporting research and development programs.

 Biotech Momentum on ASX: Could This Medical Tech Story Surge?

Biotech Momentum on ASX: Could This Medical Tech Story Surge?

March 11, 2026 12:37 PM AEDT| By Sam

Metal Powder Works has introduced additional ordinary shares for quotation on the ASX, expanding its capital base and illustrating how evolving capital structures influence liquidity and trading activity.

 Imugene Trial Update Sparks Hope in Cancer Immunotherapy

Imugene Trial Update Sparks Hope in Cancer Immunotherapy

March 10, 2026 07:42 PM AEDT| By Sam

Imugene’s experimental immunotherapy gains attention after a trial participant enters remission. The development highlights progress in advanced lymphoma research and evolving cancer treatment approaches.

 CleanSpace Share Quotation Update Highlights ASX Market

CleanSpace Share Quotation Update Highlights ASX Market

March 10, 2026 06:10 PM AEDT| By Sam

A listed safety technology company applied for quotation of additional ordinary shares, reflecting routine compliance with exchange regulations while highlighting ongoing developments within Australia’s evolving public market landscape.

 4DMedical’s Next Chapter: Can Innovation Reshape Market Confidence?

4DMedical’s Next Chapter: Can Innovation Reshape Market Confidence?

March 10, 2026 05:38 PM AEDT| By Sam

Healthcare technology companies continue shaping Australia’s market landscape as innovation in respiratory imaging and medical diagnostics attracts attention for its potential role in improving clinical insights and treatment pathways.

 Lung Imaging Story: What’s Next for 4DMedical?

Lung Imaging Story: What’s Next for 4DMedical?

March 10, 2026 05:19 PM AEDT| By Sam

4DMedical’s latest financial update highlights stable revenue but rising losses, shifting investor attention toward technology adoption, funding resilience, and the evolving role of advanced lung imaging in respiratory healthcare innovation.

 Imugene Azer-Cel Trial Sparks Hope in Blood Cancer Fight

Imugene Azer-Cel Trial Sparks Hope in Blood Cancer Fight

March 10, 2026 04:30 PM AEDT| By Sam

Imugene’s azer-cel immunotherapy gains attention after a remission case in its clinical trial. The CAR-T therapy program is advancing research for difficult-to-treat blood cancers across global study sites.

 Dimerix Advances Within the All Ordinaries Biotech Space

Dimerix Advances Within the All Ordinaries Biotech Space

March 10, 2026 02:00 PM AEDT| By Sam

Dimerix completes adult dosing in its ACTION3 phase trial, with enrolment surpassing target, reinforcing its progress within the All Ordinaries biotech sector.

 Why Did the ASX Healthcare Sector Shift Midday Within the ASX 200 Market?

Why Did the ASX Healthcare Sector Shift Midday Within the ASX 200 Market?

March 10, 2026 01:45 PM AEDT| By Sam

Australia’s healthcare sector recorded varied midday activity within the ASX market as biotechnology, pharmaceutical, and medical technology companies remained active across benchmark indices.

 CSL Limited Movement Draws Attention in ASX 200 Healthcare Segment

CSL Limited Movement Draws Attention in ASX 200 Healthcare Segment

March 10, 2026 01:12 PM AEDT| By Sam

CSL Limited’s recent movement highlights how earnings updates can influence healthcare sector sentiment within the ASX 300 and ASX All Ords.

 ASX 200 Healthcare Stock Surges Amid Market Rotation

ASX 200 Healthcare Stock Surges Amid Market Rotation

March 10, 2026 12:56 PM AEDT| By Sam

An ASX 200 healthcare stock climbs strongly as sector rotation supports defensive names within the ASX 300 and All Ordinaries.

 Neuren Pharmaceuticals Slides Amid ASX 300 Healthcare Volatility

Neuren Pharmaceuticals Slides Amid ASX 300 Healthcare Volatility

March 10, 2026 12:27 PM AEDT| By Sam

Neuren Pharmaceuticals declines following earnings, reflecting valuation recalibration within the ASX 300 and ASX All Ords healthcare segment.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.